A detailed history of Rafferty Asset Management, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 371,034 shares of BCRX stock, worth $2.81 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
371,034
Previous 465,731 20.33%
Holding current value
$2.81 Million
Previous $2.88 Million 2.05%
% of portfolio
0.01%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$6.41 - $8.69 $607,007 - $822,916
-94,697 Reduced 20.33%
371,034 $2.82 Million
Q2 2024

Aug 13, 2024

SELL
$4.13 - $6.79 $4.56 Million - $7.5 Million
-1,104,051 Reduced 70.33%
465,731 $2.88 Million
Q1 2024

May 13, 2024

BUY
$4.89 - $7.65 $3 Million - $4.7 Million
614,195 Added 64.27%
1,569,782 $7.97 Million
Q4 2023

Feb 13, 2024

BUY
$4.98 - $6.77 $735,541 - $999,922
147,699 Added 18.28%
955,587 $5.72 Million
Q3 2023

Nov 13, 2023

SELL
$6.71 - $7.92 $1.12 Million - $1.32 Million
-167,075 Reduced 17.14%
807,888 $5.72 Million
Q2 2023

Aug 11, 2023

BUY
$6.96 - $8.81 $1.07 Million - $1.36 Million
154,442 Added 18.82%
974,963 $6.86 Million
Q1 2023

May 11, 2023

BUY
$7.94 - $11.84 $416,437 - $620,984
52,448 Added 6.83%
820,521 $6.84 Million
Q4 2022

Feb 13, 2023

BUY
$10.5 - $14.2 $2.65 Million - $3.59 Million
252,845 Added 49.07%
768,073 $8.82 Million
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $1.38 Million - $1.89 Million
127,901 Added 33.02%
515,228 $6.49 Million
Q2 2022

Aug 12, 2022

BUY
$7.89 - $17.88 $438,794 - $994,378
55,614 Added 16.77%
387,327 $4.1 Million
Q1 2022

May 13, 2022

SELL
$11.56 - $19.76 $1.4 Million - $2.39 Million
-120,924 Reduced 26.72%
331,713 $5.39 Million
Q4 2021

Feb 10, 2022

BUY
$11.18 - $15.46 $2.77 Million - $3.83 Million
247,639 Added 120.8%
452,637 $6.27 Million
Q3 2021

Nov 10, 2021

BUY
$14.21 - $17.65 $694,741 - $862,926
48,891 Added 31.32%
204,998 $2.95 Million
Q2 2021

Aug 10, 2021

SELL
$9.5 - $17.24 $1.02 Million - $1.85 Million
-107,477 Reduced 40.78%
156,107 $2.47 Million
Q1 2021

May 10, 2021

BUY
$7.37 - $13.61 $1.11 Million - $2.06 Million
151,233 Added 134.61%
263,584 $2.68 Million
Q4 2020

Feb 10, 2021

SELL
$3.37 - $8.61 $1.4 Million - $3.56 Million
-413,951 Reduced 78.65%
112,351 $837,000
Q3 2020

Nov 13, 2020

BUY
$3.43 - $5.53 $1.04 Million - $1.68 Million
303,685 Added 136.42%
526,302 $1.81 Million
Q2 2020

Aug 07, 2020

BUY
$1.9 - $5.61 $390,292 - $1.15 Million
205,417 Added 1194.28%
222,617 $1.06 Million
Q1 2020

May 15, 2020

SELL
$1.6 - $4.11 $206,214 - $529,713
-128,884 Reduced 88.23%
17,200 $34,000
Q4 2019

Feb 10, 2020

SELL
$1.59 - $3.45 $199,214 - $432,257
-125,292 Reduced 46.17%
146,084 $504,000
Q3 2019

Nov 14, 2019

SELL
$2.5 - $3.73 $272,795 - $407,010
-109,118 Reduced 28.68%
271,376 $777,000
Q2 2019

Aug 09, 2019

BUY
$2.91 - $9.15 $801,571 - $2.52 Million
275,454 Added 262.24%
380,494 $1.44 Million
Q1 2019

May 15, 2019

BUY
$7.38 - $9.72 $775,195 - $1.02 Million
105,040 New
105,040 $855,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.